Literature DB >> 22064363

Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts.

Nilesh W Gaikwad1, William J Bodell.   

Abstract

Tamoxifen (TAM) is extensively used for the treatment and prevention of breast cancer. Associated with TAM treatment is a two- to eightfold increase in risk of endometrial cancer. To understand the mechanisms associated with this increased risk several pathways for TAM metabolism and DNA adduct formation have been studied. The purpose of this study was to investigate the role of peroxidase enzymes in the metabolism of TAM and its activation to form DNA adducts. Using advanced tandem mass spectrometry we have investigated the peroxidase-mediated metabolism of TAM. Incubation of TAM with horseradish peroxidase (HRP) and H(2)O(2) produced multiple metabolites. Electrospray ionization-MS/MS analysis of the metabolites demonstrated a peak at 301.3m/z with daughter ions at 183.0, 166.9, 128.9, and 120.9m/z, which identified the metabolite as metabolite E (ME). The levels of ME were significantly inhibited by the addition of ascorbic acid to the incubation mixture. Co-incubation of either TAM or ME and DNA with HRP and H(2)O(2) produced three DNA adducts with a RAL of 1.97±0.01×10(-7) and 8.45±2.7×10(-7). Oxidation of ME with MnO(2) produced metabolite E quinone methide (MEQM). Furthermore, incubation of either TAM or ME with HRP and H(2)O(2) resulted in formation of MEQM. Reaction of calf thymus DNA with MEQM produced three DNA adducts with a RAL of 9.8±1.0×10(-7). Rechromatography analyses indicated that DNA adducts 1, 2, and 3 formed in the HRP activation of either TAM or ME were the same as those formed by the chemical reaction of DNA with MEQM. The results of these studies demonstrate that peroxidase enzymes can both metabolize TAM to form the primary metabolite ME and activate ME to a quinone methide intermediate, which reacts with DNA to form adducts. It is possible that peroxidase enzymes or peroxidase-like activity in endometrium could contribute to the formation of DNA damage and genotoxic effects in endometrium after TAM administration. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22064363      PMCID: PMC3253372          DOI: 10.1016/j.freeradbiomed.2011.10.433

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  65 in total

1.  Determination of tamoxifen and its metabolites in endometrial tissue of long-term treated women

Authors: 
Journal:  Eur J Cancer       Date:  2000-09       Impact factor: 9.162

2.  Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer.

Authors:  Koji Yamazawa; Yukimasa Miyazawa; Masato Suzuki; Maki Wakabayashi; Hiroshi Kaku; Hideo Matsui; Souei Sekiya
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

Review 3.  Antiestrogen therapy: uncertainties and risk assessment.

Authors:  L L Smith; I N White
Journal:  Oncology (Williston Park)       Date:  1998-03       Impact factor: 2.990

4.  Formation of DNA adducts by microsomal and peroxidase activation of p-cresol: role of quinone methide in DNA adduct formation.

Authors:  N W Gaikwad; W J Bodell
Journal:  Chem Biol Interact       Date:  2001-12-21       Impact factor: 5.192

5.  High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer.

Authors:  Francesco Sesti; Lodovico Patrizi; Beatrice Ermini; Giampiero Palmieri; Augusto Orlandi; Emilio Piccione
Journal:  Gynecol Obstet Invest       Date:  2005-05-25       Impact factor: 2.031

6.  Nuclease P1-mediated enhancement of sensitivity of 32P-postlabeling test for structurally diverse DNA adducts.

Authors:  M V Reddy; K Randerath
Journal:  Carcinogenesis       Date:  1986-09       Impact factor: 4.944

7.  Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.

Authors:  G C Hard; M J Iatropoulos; K Jordan; L Radi; O P Kaltenberg; A R Imondi; G M Williams
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

8.  Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its alpha-hydroxy and alpha,4-dihydroxy derivatives.

Authors:  L M Notley; K H Crewe; P J Taylor; M S Lennard; E M J Gillam
Journal:  Chem Res Toxicol       Date:  2005-10       Impact factor: 3.739

9.  Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts.

Authors:  A M Davies; E A Martin; R M Jones; C K Lim; L L Smith; I N White
Journal:  Carcinogenesis       Date:  1995-03       Impact factor: 4.944

10.  High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.

Authors:  U Magriples; F Naftolin; P E Schwartz; M L Carcangiu
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

View more
  1 in total

1.  Radiosensitization of human glioma cells by tamoxifen is associated with the inhibition of PKC-ι activity in vitro.

Authors:  Lei Yang; Xiaopeng Yuan; Jie Wang; Cheng Gu; Haowen Zhang; Jiahua Yu; Fenju Liu
Journal:  Oncol Lett       Date:  2015-05-11       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.